Cellect Biotechnology and Canndoc Ltd. to Enter Into Strategic Pharma Grade Cannabis Commercial Deal for Reduction in Opioid Usage

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint
InterCure Provides an Update Regarding Nir Oz Facility
InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain
InterCure Wins Cannolam Arbitration Proceeding
InterCure Provides an Update Regarding the Security Situation in Israel
InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE
InterCure Provides an Update About The Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.